Skip to main content

Advertisement

SpringerLink
Log in

Decade in review—kidney cancer

Discoveries, therapies and opportunities

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

Several advances in kidney cancer have occurred over the past decade, including the discovery of mutations in chromatin remodelling genes and genomic heterogeneity in clear cell renal cell carcinoma (ccRCC). Altered metabolic patterns in ccRCC and papillary RCC have become apparent, and new drugs for ccRCC have been approved.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Genomic heterogeneity in different regions of ccRCC.

References

  1. Jonasch, E. & Motzer, R. J. Ten years of progress in renal cell carcinoma. J. Natl Compr. Canc. Netw. 10, 690–693 (2012).

    Article  Google Scholar 

  2. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360–363 (2010).

    Article  CAS  Google Scholar 

  3. Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011).

    Article  CAS  Google Scholar 

  4. The Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Clear Cell Renal Cell Carcinoma. Nature 499, 43–49 (2013).

  5. Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380–384 (2011).

    Article  Google Scholar 

  6. Mullen, A. R. et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481, 385–388 (2011).

    Article  Google Scholar 

  7. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).

    Article  CAS  Google Scholar 

  8. Tong, W. H. et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 20, 315–327 (2011).

    Article  CAS  Google Scholar 

  9. Adam, J. et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20, 524–537 (2011).

    Article  CAS  Google Scholar 

  10. Ooi, A. et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 20, 511–523 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologic Oncology Branch, National Cancer Institute, 10 Center Drive, MSC 1107, CRC Room 1W-5940, Bethesda, 20892-1107, MD, USA

    W. Marston Linehan & Christopher J. Ricketts

Authors
  1. W. Marston Linehan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. Ricketts
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Marston Linehan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Linehan, W., Ricketts, C. Discoveries, therapies and opportunities. Nat Rev Urol 11, 614–616 (2014). https://doi.org/10.1038/nrurol.2014.262

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2014.262

  • Springer Nature Limited

This article is cited by

Search

Navigation